FierceBiotech

In a Post-Hoc Analysis, JANUVIA® (sitagliptin), Merck’s Diabetes Medicine, Compared with a Sulfonylurea (Glipizide)

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- In a new post-hoc analysis presented for the first time at the American Diabetes Association (ADA) 70 th Annual Scientific Sessions, significantly more ...
Business Wire

TECOS, Merck’s Cardiovascular Safety Trial of JANUVIA (sitagliptin), Met Primary Endpoint in Patients with Type 2 Diabetes

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the primary results of the Trial Evaluating Cardiovascular Outcomes with ...
Business Wire

Research and Markets: Januvia (sitagliptin) - Type 2 Diabetes Forecast and Market Analysis to 2022

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/q7v2fq/januvia_type_2) has announced the addition of the "Januvia (Type 2 ...
FiercePharma

Merck Announces the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) Met Primary Endpoint

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) of ...
FierceBiotech

Merck Receives Positive CHMP Opinion for JANUVIA® (sitagliptin) and JANUMET® (sitagliptin/metformin) as Add-On to Insulin

Merck Receives Positive CHMP Opinion for JANUVIA® (sitagliptin) and JANUMET® (sitagliptin/metformin) as Add-On to Insulin in the European Union WHITEHOUSE STATION ...
Monthly Prescribing Reference

Phase 3 Study of Dapagliflozin in Combination with Sitagliptin for Type 2 Diabetes

Bristol-Myers Squibb and AstraZeneca announced results from a Phase 3 clinical study that showed the investigational compound dapagliflozin demonstrated significant reductions in HbA1C compared with ...
sciencex

Late-breaking observational data show patients with type 2 diabetes taking JANUVIA® (sitagliptin) and metformin init

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a late-breaking observational study that assessed the differences in time to initiation of insulin ...
Insurancenewsnet.com

Latest Januvia Lawsuits Alleging Pancreatic Cancer Help: Resource4thePeople Reports Cases Continue To Be Filed in Federal Multidistrict Litigation

Resource4thePeople announced today its latest update for consumers who are following the progress of lawsuits alleging that a class of diabetes medications including Januvia, Janumet, Byetta and ...
Medscape

Sitagliptin linked to acute pancreatitis, FDA warns

Silver Spring, MD -The US Food and Drug Administration (FDA) announced that it is revising prescribing information for diabetes drugs sitagliptin (Januvia, Merck) and sitagliptin/metformin (Janumet, ...
Medscape

Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin for Patients With Type 2 Diabetes Mellitus

The two incretin hormones, glucagon-like peptide (GLP)-1 and glucose-dependent insulinotropic polypeptide potentiate nutrient-dependent insulin secretion following meal ingestion. Metabolic control ...
Healio

Liraglutide more effective than sitagliptin for overall type 2 diabetes management

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Switching to the glucagon-like peptide-1 ...